Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

Evidence for efficacy is based on the results from the ELARA study
24 Jun 2022
Cell-Based Therapy
Lymphomas

On 27 May 2022, the US Food and Drug Administration (FDA) granted accelerated approval to tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

The approval was based on the ELARA study (NCT03568461), a multicentre, single-arm, open-label study evaluating tisagenlecleucel, a CD19-directed chimeric antigen receptor (CAR) T cell therapy, in adult patients who were refractory or relapsed within 6 months after completion of two or more lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent) or relapsed after autologous haematopoietic stem cell transplant. Following lymphodepleting chemotherapy, tisagenlecleucel was administered as a single intravenous infusion with a target dose of 0.6 to 6.0 x 108 CAR-positive viable T cells.

The main efficacy measures were overall response rate (ORR) and duration of response (DoR) as determined by an independent review committee. Among 90 patients in the primary efficacy analysis, the ORR was 86% (95% confidence interval [CI] 77, 92) with a complete response (CR) rate of 68% (95% CI 57, 77). The median DoR was not reached, with 75% (95% CI 63, 84) of responders still in response at 9 months. For all patients who underwent leukapheresis (n = 98), the ORR was 86% (95% CI 77, 92) with a CR rate of 67% (95% CI 57, 76).

The most common adverse reactions (>20%) occurring in patients were cytokine release syndrome, infection, fatigue, musculoskeletal pain, headache, and diarrhoea.

The recommended tisagenlecleucel dose is 0.6 to 6.0 x 108 CAR-positive viable T cells.

Full prescribing information for Kymriah is available here.

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application 1 month ahead of the FDA goal date.

This application was granted priority review and regenerative medicine advanced therapy designation. The application also was granted orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.